Want to see INKT full AI Analyst Report?
INKT Stock Chart & Stats
$11.07
$0.71(6.85%)
At close: 4:00 PM EDT
$11.07
$0.71(6.85%)
Day’s Range― - ―
52-Week Range$8.48 - $18.17
Previous CloseN/A
Volume20.36K
Average Volume (3M)39.56K
Market Cap
$52.31M
Enterprise Value$41.00
Total Cash (Recent Filing)$9.53M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Aug 12, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding4,981,899
10 Day Avg. Volume31,712
30 Day Avg. Volume39,559
Financial Highlights & Ratios
PEG Ratio-3.68
Price to Book (P/B)-3.35
Price to Sales (P/S)0.00
P/FCF Ratio-8.04
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$35.00Price Target Upside216.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.75
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Robust Survival Signal In Refractory Gastric CancerAn observed median overall survival >23 months in heavily pretreated, checkpoint‑refractory gastric cancer indicates a potentially differentiated clinical activity for MiNK’s iNKT platform. Durable survival signals can attract partners, de-risk clinical strategy and support cross-indication development and regulatory interest.
Randomized Phase II ARDS Trial With Seamless Phase II/III DesignLaunching a randomized, seamless Phase II/III ARDS study with planned FDA engagement and near-term readouts materially strengthens the company’s clinical development path. A successful seamless design can accelerate registrational decisions and reduce time-to-proof, improving the platform’s strategic value.
Scalable Off-the-shelf ManufacturingA scalable, cryopreserved, off-the-shelf product that avoids HLA matching and lymphodepletion addresses major operational barriers for cell therapies. Durable manufacturing scale capability reduces per-dose cost, supports rapid ICU deployment, and underpins broader commercial and partnership potential across indications.
Bears Say
Zero Revenue And Persistent Net LossesMiNK remains a pre-revenue biotech with recurring operating losses and negative free cash flow, a durable characteristic that necessitates external funding. Persistent losses limit runway, increase dilution risk, and constrain the company’s ability to self-fund multi-indication development without partnering or capital raises.
Modest Cash Runway And Near-term Financing RiskA small cash balance relative to ongoing programs and trial execution needs creates enduring financing risk. Even with a stated ~12‑month runway, executing a randomized ARDS trial and parallel programs will likely require additional capital or partnerships, exposing the company to dilution or funding delays.
Balance-sheet Instability And Negative Equity HistoryNegative historical equity and a recent balance-sheet remeasurement introduce structural financial uncertainty. Such instability weakens borrowing capacity, complicates partner diligence, and increases execution risk because capital structure irregularities can affect future financing terms and strategic flexibility.
MiNK Therapeutics News
INKT FAQ
What was MiNK Therapeutics’s price range in the past 12 months?
MiNK Therapeutics lowest stock price was $8.48 and its highest was $18.17 in the past 12 months.
What is MiNK Therapeutics’s market cap?
MiNK Therapeutics’s market cap is $52.31M.
When is MiNK Therapeutics’s upcoming earnings report date?
MiNK Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 10 days.
How were MiNK Therapeutics’s earnings last quarter?
MiNK Therapeutics released its earnings results on May 15, 2026. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is MiNK Therapeutics overvalued?
According to Wall Street analysts MiNK Therapeutics’s price is currently Undervalued.
Does MiNK Therapeutics pay dividends?
MiNK Therapeutics does not currently pay dividends.
What is MiNK Therapeutics’s EPS estimate?
MiNK Therapeutics’s EPS estimate is -0.6.
How many shares outstanding does MiNK Therapeutics have?
MiNK Therapeutics has 4,981,899 shares outstanding.
What happened to MiNK Therapeutics’s price movement after its last earnings report?
MiNK Therapeutics reported an EPS of -$0.57 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.998%.
Which hedge fund is a major shareholder of MiNK Therapeutics?
Currently, no hedge funds are holding shares in INKT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MiNK Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (216.17% Upside)
$35.00 (216.17% Upside)
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
143.17%
Trailing 12-Months
Company Description
MiNK Therapeutics
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
INKT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates strong scientific and early clinical momentum: context-dependent mechanistic data, an unusually long median overall survival signal in refractory gastric cancer (>23 months), initiation of a randomized 90‑patient Phase II ARDS trial with a seamless Phase II/III design, scalable off‑the‑shelf manufacturing, and partnerships that reduce dilution. Offsetting risks include a modest cash balance (~$9.5M), ongoing operating losses, the early-stage nature of much of the efficacy data (investigator trials, translational findings, case reports), and typical ARDS and trial execution risks (biologic heterogeneity, prior failures in cell therapy, logistical/geopolitical complexities). On balance, the highlights (clinical signal, trial initiation, manufacturing readiness, partnerships and planned near‑term readouts) outweigh the lowlights, but execution and financing will be critical over the next 12 months.View all INKT earnings summariesINKT Stock 12 Month Forecast
Average Price Target
$35.00
▲(216.17% Upside)
Technical Analysis
Ownership Overview
4.80% Insiders
1.43% Mutual Funds
0.33% Other Institutional Investors
91.93% Public Companies and
Individual Investors